We thank the editor to offer us the opportunity to improve this editorial and the reviewers' favorable comments and insights, which we are happy to incorporate into the revised manuscript. All corrections are highlighted in the revised version. The responses to each of the comments from the reviewers are provided below.

## Reviewer #1:

Specific Comments to Authors: The title states: prevention of diabetic nephropathy and the text is. Of about nephropathy

**Response:** Thanks for the reviewer favorable comments. We have tried to make the consistent and matching.

## Reviewer #2:

Specific Comments to Authors:

The authors primarily emphasize the therapeutic potential of 18β-GA for diabetic nephropathy in this editorial. However, in the Abstract section, it was mentioned that the authors initially commented on a study investigating the preventive effect of atorvastatin on diabetic cardiomyopathy in db/db T2DM mice. I believe that including this sentence in the Abstract section is not necessary.

**Response:** Thanks for the constructive suggestions. It has been deleted from abstract.

In this editorial, the authors present several facts demonstrating the protective roles and underlying mechanisms of  $18\beta$ -GA. It would be beneficial for the authors to summarize these findings in a figure.

**Response:** Thanks for the reviewer favorable comments. We also appreciate the reviewer's insightful suggestion of a figure; therefore, we have provided a figure in the revision of it.